

# 紫杉醇联合卡铂新辅助化疗治疗Ⅲ期胃癌的疗效及安全性

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年10期 页码: 1765-1768 栏目: 论著 (消化·泌尿系肿瘤) 出版日期: 2019-04-08

**Title:** The effect and security of neoadjuvant chemotherapy (paclitaxel plus carboplatin) on gastric cancer of III stage

**作者:** 彭涛<sup>1</sup>; 娄展<sup>1</sup>; 张育<sup>1</sup>; 王国强<sup>2</sup>; 曹铭富<sup>3</sup>; 高强<sup>3</sup>; 李曙光<sup>1</sup>

1.河北北方学院附属第一医院,河北 张家口 075000;2.张家口市第一医院,河北 张家口 075000;3.河北北方学院,河北 张家口 075000

**Author(s):** Peng Tao<sup>1</sup>; Lou Zhan<sup>1</sup>; Zhang Yu<sup>1</sup>; Wang Guoqiang<sup>2</sup>; Cao Mingfu<sup>3</sup>; Gao Qiang<sup>3</sup>; Li Shuguang<sup>1</sup>

1.The First Affiliated Hospital of Hebei North University,Hebei Zhangjiakou 075000,China;2.The First Hospital of Zhangjiakou,Hebei Zhangjiakou 075000,China;3.Hebei North University,Hebei Zhangjiakou 075000,China.

**关键词:** 胃癌; 新辅助化疗; 紫杉醇; 卡铂

**Keywords:** gastric cancer; neoadjuvant chemotherapy; paclitaxel; carboplatin

**分类号:** R735.2

**DOI:** 10.3969/j.issn.1672-4992.2019.10.025

**文献标识码:** A

**摘要:** 目的: 评价新辅助化疗(紫杉醇联合卡铂方案,即TC方案)对Ⅲ期胃癌疗效及安全性的影响。方法: 回顾性分析河北北方学院附属第一医院胃肠肿瘤外科2013年1月至2018年1月收治的临床确诊为Ⅲ期胃癌48例患者临床病例资料。所有患者术前均行TC方案化疗(3周期),而后行手术切除,对新辅助化疗的疗效及安全性指标进行比较及分析。结果: 入组48例患者中,43例患者经新辅助化疗后肿瘤明显降期,降期比例为43/48(89.6%),其中4例患者达到完全缓解,行临床TNM分期和病理学TNM分期比较,肿瘤降期具有统计学意义( $P < 0.05$ ),肿瘤消退率为89.6%,总的降期率为89.6%。不良反应主要表现为血液毒性(白细胞减少、红细胞减少、血小板减少)、胃肠道反应和脱发,以I-II级不良反应为主,所有不良反应均经对症处理后症状减轻或者消失,全组无化疗相关性死亡病例。结论: Ⅲ期胃癌经TC方案新辅助化疗后,临床效果好,不良反应低,具有很强可行性。

**Abstract:** Objective: To evaluate the effect and security of neoadjuvant chemotherapy (paclitaxel plus carboplatin TC) on gastric cancer of III stage. Methods: Clinical data of 48 patients with gastric cancer in the First Affiliated Hospital of Hebei North University between January 2013 and January 2018 were retrospectively analysed. All patients underwent TC regimen chemotherapy (3 cycles) pre-operation, and then the efficacy and safety of neoadjuvant chemotherapy were compared and analyzed. Results: Among the 48 patients in the group, 43 of the patients were significantly reduced staging after neoadjuvant chemotherapy. The reduction rate was 43/48 (89.6%), including 4 patients had achieved complete remission. Compared with clinical TNM stage and pathological TNM stage, the tumor reduction was statistically significant ( $P < 0.05$ ). Tumor regression grade was 89.6%. The total drop stage was at a rate of 89.6%. Adverse reactions were mainly manifested as blood toxicity (leukocyte reduction, erythrocyte reduction, thrombocytopenia), gastrointestinal reaction and hair loss. It was mainly a negative reaction of I or II. All adverse reactions were alleviated or disappeared after symptomatic treatment. There were no chemotherapy related deaths in the whole group. Conclusion: III stage gastric cancer after neoadjuvant chemotherapy of TC alternatives has good clinical effect, and the adverse reactions are low. It has a strong feasibility.

## 参考文献/REFERENCES

- [1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA: A Cancer Journal for Clinicians, 2016, 66(2): 115-132.
- [2] Sasako M. Principles of surgical treatment for curable gastric cancer [J]. Clin J Oncol, 2003, 21(s): 274-275.
- [3] Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1 D2 trial [J]. Lancet Oncol, 2010, 11(5): 439-449.

- [4] Ychou M,Boige V,Pignon J,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:ASn fnclcc and fcd multicenter phase III trial [J] .J Clin Oncol,2011,29(13):1715-1721.
- [5] Ferri L,Ades S,Alcindor T,et al.Perioperative docetaxel,cisplatin,and 5-fluorouracil (dcf) for locally advanced esophageal and gastric adenocarcinoma:a multicenter phase II trial [J] .Ann Oncol,2012,23(6):1512-1517.
- [6] Ychou M,Boige V,Pignon J,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:An fnclcc and fcd multicenter phase III trial [J] .J Clin Oncol,2011,29(13):1715-1721.
- [7] Li Z,Koh CE,Bu Z,et al.Neoadjuvant chemotherapy with folfox:Improved outcomes in Chinese patients with locally advanced gastric cancer [J] .J Surg Oncol,2012,105(8):793-799.
- [8] Tsuburaya A,Mizusawa J,Tanaka Y,et al.Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para -aortic lymph node dissection for gastric cancer with extensive lymph node metastasis [J] .Br J Surg,2014,101(6):653-660.
- [9] Cunningham D,Allum WH,Stenning SP,et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J] .N Engl J Med,2006,355(1):11-20.
- [10] Amin MB,Edge SB,Greene FL,et al.AJCC cancer staging manual.8th ed [J] .New York:Springer,2016:203-220.
- [11] Kautio AL,Haanpaa M,Kautiainen H,et al.Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy- induced peripheral neuropathy [J] .Anticancer Res,2011,31(10):3493-3496.
- [12] Chen ZW,Liao ML.Evaluation of tumor response with RESIST criteria [J] .China Cancer,2004,13(10):616-618.
- [13] Kim BC.Prognostic significance of tumor regression grade after preoperative chemoradiotherapy for rectal cancer [J] .J Korean Soc Coloproctol,2011,27(1):1-2.
- [14] Wilke H,Preusser P,Fink U,et al.Preoperative chemotherapy in locally advanced and nonresectable gastric cancer:A phase II study with etoposide, doxorubicin,and cisplatin [J] .J Clin Oncol,1989,7(9):1318-1326.
- [15] Von Minckwitz G,Costa SD,Raab G,et al.Dose-dense doxorubicin,docetaxel,and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast:A randomized,controlled open phase IIb study [J] .J Clin Oncol,2001,19(15):3506-3515.
- [16] Paik S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer [J] .N Engl J Med,2004,351(27):2817-2826.
- [17] Moreira E,Paulino E,Ingles Garces AH,et al.Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer:A retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA) [J] .Med Oncol,2018,35(3):20.
- [18] Okuda K,Yano M,Tatematsu T,et al.S-1 vs paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIa non-small-cell lung cancer [J] .Mol Clin Oncol,2018,8(1):73-79.
- [19] Yazawa H,Hiraiwa T,Ito F,et al.Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin [J] .Obstet Gynecol Sci,2017,60(6):587-592.
- [20] Sandercock J,Parmer MK,Torri V,et al.First-line treatment for advanced ovarian cancer:Paclitaxel,platinym,and the evidence [J] .Br J Cancer,2002,87(8):815-824.
- [21] Prithviraj GK,Baksh K,Fulp W,et al.Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer [J] .Dis Esophagus,2015,28(8):782-787.
- [22] Mobayed M,Heilbrun,Shields AF,et al.Safety and feasibility of carboplatin and paclitaxel followed by fluoropyrimidine analogs and radiation as adjuvant therapy for gastric cancer [J] .Case Rep Oncol,2009,2(3):220-228.

---

**备注/Memo:** 河北省政府资助临床医学优秀人才培养和基础课题研究项目 (编号: 361009)

---

更新日期/Last Update: 1900-01-01